Physician profile
Peter Fred Levins
NPI 1407876303
$2,305.70
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,910 · 2020: $201 · 2022: $79.89 · 2023: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $114.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $1,006.13 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $258.78 | 2019-2020 | |
| Amgen INC. | $111.80 | 2019-2020 | |
| Pfizer INC. | $107.50 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.12 | 2019-2023 | Xifaxan |
| Novo Nordisk INC | $93.74 | 2019-2020 | |
| Glaxosmithkline, LLC. | $87.02 | 2019-2023 | Shingrix, Arexvy |
| Allergan, INC. | $78.30 | 2019-2020 | |
| Abbvie INC. | $71.96 | 2019-2022 | |
| Sanofi Pasteur INC. | $62.73 | 2019-2022 | |
| Astellas Pharma US INC | $54.45 | 2019-2020 | |
| Lilly USA, LLC | $48.31 | 2019-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $40.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.11 | 2019 | |
| Genentech USA, INC. | $30.47 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.43 | 2019 | |
| Indivior INC. | $16.96 | 2023 | Sublocade |
| Amarin Pharma, INC. | $14.97 | 2019 | |
| Merck Sharp & Dohme LLC | $12.11 | 2019 | |
| Medtronic USA, INC. | $11.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.56 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Levins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.